...Chugai and Taisho launched a monthly oral formulation of Boniva ibandronate in Japan to treat osteoporosis... ...of a 100 mg tablet, the recommended monthly dose, is Y2,790 ($25.11). Chugai partnered with Taisho... ...owned by Roche (see BioCentury, Sept. 18, 2006). Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan Taisho...
...Chugai and Taisho said Japan approved a monthly oral formulation of Boniva ibandronate to treat osteoporosis... ...treat osteoporosis. Japan approved a monthly IV formulation of Boniva in 2013. Chugai partnered with Taisho... ...oral formulation to prevent osteoporosis in postmenopausal women. Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan Taisho...
...2009, the JV paid an undisclosed sum to acquire a majority stake in generics play Taisho... ...and Welfare (MHLW), Tokyo, Japan Pharmaceutical Research and Manufacturers of America (PhRMA) , Washington, D.C. Taisho...
...Toyama co-developed Careram/Kolbet in Japan. Eisai and Taisho Toyama Pharmaceutical Co. Ltd., a JV between Taisho... ...a subsidiary of Fujifilm Holdings Corp. (Tokyo:4901, Tokyo, Japan). Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Taisho...
...Ablynx granted Taisho exclusive, Japanese rights to develop and commercialize ozoralizumab to treat rheumatoid arthritis. Ablynx... ...million up front and is eligible to receive undisclosed development and commercial milestones and royalties. Taisho... ...is a Nanobody against tumor necrosis factor (TNF) alpha . Ablynx N.V. (Euronext:ABLX), Ghent, Belgium Taisho Pharmaceutical Co. Ltd....
...Chugai and Taisho launched a monthly oral formulation of Boniva ibandronate in Japan to treat osteoporosis... ...of a 100 mg tablet, the recommended monthly dose, is Y2,790 ($25.11). Chugai partnered with Taisho... ...owned by Roche (see BioCentury, Sept. 18, 2006). Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan Taisho...
...Chugai and Taisho said Japan approved a monthly oral formulation of Boniva ibandronate to treat osteoporosis... ...treat osteoporosis. Japan approved a monthly IV formulation of Boniva in 2013. Chugai partnered with Taisho... ...oral formulation to prevent osteoporosis in postmenopausal women. Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan Taisho...
...2009, the JV paid an undisclosed sum to acquire a majority stake in generics play Taisho... ...and Welfare (MHLW), Tokyo, Japan Pharmaceutical Research and Manufacturers of America (PhRMA) , Washington, D.C. Taisho...
...Toyama co-developed Careram/Kolbet in Japan. Eisai and Taisho Toyama Pharmaceutical Co. Ltd., a JV between Taisho... ...a subsidiary of Fujifilm Holdings Corp. (Tokyo:4901, Tokyo, Japan). Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Taisho...
...Ablynx granted Taisho exclusive, Japanese rights to develop and commercialize ozoralizumab to treat rheumatoid arthritis. Ablynx... ...million up front and is eligible to receive undisclosed development and commercial milestones and royalties. Taisho... ...is a Nanobody against tumor necrosis factor (TNF) alpha . Ablynx N.V. (Euronext:ABLX), Ghent, Belgium Taisho Pharmaceutical Co. Ltd....